Dr. Rugo Discusses Late Recurrence in HR+ Breast Cancer

Hope Rugo, MD
Published: Monday, Oct 30, 2017



Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses late recurrence in patients with hormone receptor (HR)-positive breast cancer.

Rugo says that the idea of latency in HR-positive disease is still not fully understood.

Currently, trials involving CDK4/6 inhibitors and PI3K inhibitors are garnering interest in this population. Rugo says that it remains to be seen whether these agents are the key to understanding late recurrence.
 


Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses late recurrence in patients with hormone receptor (HR)-positive breast cancer.

Rugo says that the idea of latency in HR-positive disease is still not fully understood.

Currently, trials involving CDK4/6 inhibitors and PI3K inhibitors are garnering interest in this population. Rugo says that it remains to be seen whether these agents are the key to understanding late recurrence.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 16th Annual International Congress on the Future of Breast Cancer®Sep 29, 20182.0
School of Breast Oncology®: Mid-Year Video Update OnlineSep 30, 20182.0
Publication Bottom Border
Border Publication
x